Company Website

Contact Information:
Tim Hutsko
Cell: 602-908-6341
timothy.hutsko@interceptpharma.com

Virtual Exhibit Hall Home
 

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

Please visit https://www.ocaliva.com/ to obtain more information on Ocaliva.